Dublin, Ireland

Helen Reid

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2016-2021

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovations of Helen Reid: A Pioneer in Thromboxane Receptor Antagonists

Introduction: Helen Reid is a distinguished inventor based in Dublin, Ireland, known for her innovative contributions in the field of pharmaceuticals. With a remarkable portfolio of eight patents, she has made significant strides in understanding and developing thromboxane receptor antagonists, which play a crucial role in treating various human diseases.

Latest Patents: Helen Reid's latest inventions revolve around novel chemical entities that act as thromboxane (TX) A receptor, or T prostanoid receptor (TP), antagonists. Her work explores their applications in treating diseases where thromboxane and other incidental ligands of TP are influential. The compounds she has developed include a benzenesulfonyl urea, which features a substituted biphenylyloxy group and a nitrile group. These compounds have shown promising results as selective TP antagonists, suggesting a potential for targeted pharmacological therapies.

Career Highlights: Throughout her career, Helen has worked with notable institutions and companies such as University College Dublin and Atxa Therapeutics Limited. Her tenure at these establishments underscores her commitment to advancing medical science through research and invention. By focusing on thromboxane receptor antagonism, she has carved a niche for herself that may lead to significant health advancements.

Collaborations: In her innovative journey, Helen Reid has collaborated with esteemed colleagues such as B Therese Kinsella and Patrick Guiry. These partnerships have not only enriched her research experience but also fostered a collaborative environment that is essential for groundbreaking inventions in the scientific community.

Conclusion: In summary, Helen Reid has emerged as a leading inventor in the field of thromboxane receptor antagonists. Her portfolio of patents exemplifies her dedication to innovation and her potential to impact the treatment of human diseases positively. As research continues to evolve, Helen's contributions will undoubtedly play a pivotal role in the future of pharmacological therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…